Journal
NEUROSCIENCE LETTERS
Volume 691, Issue -, Pages 44-50Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2018.07.038
Keywords
SV2A; PET; Synaptic density; Alzheimer's disease; Parkinson's disease; Epilepsy; Stroke; Multiple sclerosis; Huntington's disease; Autism spectrum disorder; Depression; Schizophrenia
Categories
Funding
- NIH [K01EB023312, R01AG058773]
- Yale internal funds
Ask authors/readers for more resources
Synaptic vesicle glycoprotein 2A (SV2A) is expressed ubiquitously in neurons of the central nervous system, and is the binding target of the anti-epileptic drug levetiracetam. Because of the availability of positron emission tomography (PET) ligands targeting SV2A, there is increasing enthusiasm on the use of SV2A PET to study a variety of neuropsychiatric diseases. This review discusses the recent development of radioligands for PET imaging of SV2A and their potential use in the research and diagnosis of CNS diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
